In this episode of the Nucleate podcast, Jodie Morrison, CEO of Q32 Bio, discusses her extensive career path from clinical research to executive leadership. She explains her strategic approach to leading companies, particularly in challenging "fixer-upper" scenarios where she prioritizes finding assets with "good bones" and building high-performing, mission-driven teams. She also details Q32 Bio's current focus on autoimmune disorders like alopecia areata, emphasizing the pursuit of safer biologic treatments for patients who currently face significant unmet needs. Beyond her corporate role, Morrison highlights her efforts to foster community among biotech leaders through the founding of the CEO Forum during the COVID-19 pandemic. She advocates for transparency and mentorship, particularly for women in the industry, encouraging them to "lift while they climb". Looking ahead, she expresses cautious optimism for the biotech sector, noting that while capital markets and public sentiment present hurdles, the persistent reality of human disease ensures a continuous need for scientific advancement and new therapies.
Time Stamps
01:42: Jodie’s early interest in science and the defining moment
03:31: Starting from the bottom in clinical research shaped her leadership style as a CEO
08:32: How she joined Q32 Bio and then took them public
10:11: Jodie’s inspiration to get involved with challenging companies
11:42: The emotional reward of biotech: the long hours are worthwhile to save lives
13:46: Navigating challenging situations
15:10: Q32 Bio's focus on autoimmune disorders
19:59: The origins of the CEO Forum
27:54: The "lonely" nature of being a CEO and the importance of community
30:54: Philosophy on female leadership: “lift while we climb”
34:54: How AI is involved in biotech
43:24: Navigating challenging capital markets: focus on “killer experiments” that investors want
46:47: Balancing "ethical obligation" to employees with their "fiduciary responsibility" to investors
49:56: How layoffs are “heartbreaking” but necessary to preserve capital for future drug development
56:30: The future of biotech is "cautious optimism" but needed
1:00:06: Initiatives among leaders to heal the misconception of science
01:05:01: Rapid Fire questions